James W. Mccollum - 07 Nov 2025 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)

Reporting relationship: Director
Issuer ticker: LENZ
Reported as of: 07 Nov 2025
Net transaction value: +$239,278
SEC form: 4
Accepted by SEC: 10 Nov 2025, 16:13:53 UTC
Prior SEC filing: 11 Jun 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel R. Chevallard, as Attorney-in-Fact

Key filing fact

James W. Mccollum filed Form 4 for LENZ Therapeutics, Inc. (LENZ) on 10 Nov 2025.

Key facts

This page summarizes James W. Mccollum's Form 4 filing for LENZ Therapeutics, Inc. (LENZ).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Nov 2025, 16:13.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: +$239,278.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001200889 Primary reporting owner

MCCOLLUM JAMES W

Relationship: Director
Address: C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE, SUITE 300, SOLANA BEACH
Signature: /s/ Daniel R. Chevallard, as Attorney-in-Fact
Signature date: 10 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LENZ transaction

Common Stock

Purchase

Transaction value: $239,278
Shares: +10,500
Change %
Price: $22.79
Shares after: 10,500
Date: 07 Nov 2025
Ownership: Direct
Footnotes: F1

LENZ holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 620,599
Date: 07 Nov 2025
Ownership: By trust
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the weighted average share price of an aggregate total of 10,500 shares purchased in the price range of $22.68 to $22.87 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Footnote F2

Includes 95,034 shares transferred by the Reporting Person to the McCollum Living Trust on June 6, 2024.